H.R. 1051 seeks to amend the Federal Food, Drug, and Cosmetic Act to address the approval process for generic drug applications. If the first applicant fails to start selling their drug within a set time, a later applicant could get approval under certain conditions, even if...
Simple Explanation
H.R. 1051 explains that if a company is too slow to sell a new medicine, another company might be allowed to start selling it instead, so people can get their medicines more quickly.